Code

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Retrieved on: 
Wednesday, April 3, 2024
Harvard Medical School, Dana–Farber Cancer Institute, GBM, Code, Glioblastoma, Clinical trial, Society, Brigham and Women's Hospital, Hospital, Tokyo Stock Exchange, ASCO, Neuro-Oncology (journal), Annual general meeting

LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago.

Key Points: 
  • LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) has been selected for an oral presentation at the American Society of Clinical Oncology (2024 ASCO) Annual Meeting to be held May 31 – June 4, 2024 in Chicago.
  • The oral presentation will be presented by one of the investigators of this clinical trial, Gilbert Youssef, M.D., Attending Physician at Harvard Medical School, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital.
  • The presentation details are as follows:

PLI Treatise Addresses Income Tax Opportunities and Traps for Transfers After Death

Retrieved on: 
Wednesday, March 27, 2024
Code, Income tax, Trust, Death, Life insurance

A new treatise from PLI Press, Income Taxation of Property Acquired from a Decedent , is an essential resource for tax practitioners and others who advise on estate and income tax matters, covering planning opportunities and traps to consider before and after death.

Key Points: 
  • A new treatise from PLI Press, Income Taxation of Property Acquired from a Decedent , is an essential resource for tax practitioners and others who advise on estate and income tax matters, covering planning opportunities and traps to consider before and after death.
  • “With proper, informed planning, discrepancies under the Code can be cured, traps can be avoided, and traditional estate planning techniques combined with additional income tax planning can lead to favorable results for both estate and income tax,” says the treatise’s author, Matthew S. Beard.
  • Comprehensively addressing income tax issues related to transfers after death, the publication’s topics include the exclusion from gross income under I.R.C.
  • § 1014, the application of these rules to common trust and entity structures in estate planning, substantiation, and planning opportunities and potential traps for the unwary to consider before and after death.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Retrieved on: 
Tuesday, March 26, 2024
OCT, Optical coherence tomography, Patent, Multiple sclerosis, Capsule, Tablet, Code, MD, SPRINT, MPH, Tokyo Stock Exchange, Pharmaceutical industry

Once issued, this patent is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, this patent is expected to expire no earlier than October 2039.
  • The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.
  • The allowed claims specifically cover both primary progressive multiple sclerosis and secondary progressive multiple sclerosis.
  • Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis.

Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, SVB Securities, Stifel, EUR, GJB2, Euronext Growth, Patient, Code, Interim, Reserved, Sofinnova, Clinical trial, Commercial code, Person

The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.

Key Points: 
  • The settlement-delivery of the Reserved Offering is expected to take place around April 11, 2024, subject to customary conditions.
  • This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months.
  • The capital increase enables the Company to finance its activities until the end of 2025.
  • Leerink Partners LLC (“Leerink Partners”) and Stifel Europe AG (“Stifel”) are acting as lead agents in connection with the Reserved Offering.

DOVE MARKS 20 YEARS OF REAL BEAUTY WITH A RENEWED COMMITMENT TO 'REAL' AND PLEDGE TO NEVER USE AI TO REPRESENT REAL WOMEN IN ITS ADVERTISING

Retrieved on: 
Tuesday, April 9, 2024
Research, Checklist, Pressure, Algorithm, Social media, Anxiety, University, AI, Appearance, Code, Life, Woman, Happiness, Creativity, Orientation, Artificial intelligence, Advertising, Columbidae

To mark 20 years of championing real beauty, Dove conducted a new sweeping study  to understand the state of beauty around the world today.

Key Points: 
  • To mark 20 years of championing real beauty, Dove conducted a new sweeping study  to understand the state of beauty around the world today.
  • Today, women and girls overwhelmingly agree that real beauty means being authentic, who you are, and embracing our differences.
  • "At Dove, we seek a future in which women get to decide and declare what real beauty looks like – not algorithms.
  • Dove will never stop championing better representation, taking action to break beauty stereotypes, and standing up for power of Real Beauty.

Silicon Labs xG26 Sets New Standard in Multiprotocol Wireless Device Performance

Retrieved on: 
Tuesday, April 9, 2024
Silicon Labs, Attention, SOC, Algorithm, Bluetooth Low Energy, GPIO, Bluetooth mesh networking, Acceleration, Intelligence, Internet of things, Network layer, Wireless, Internet, Sleep, ARM, Running, RAM, Silicon, Home, ARM architecture family, Radio, MG26, CCTV, CPU, Machine learning, Family, Matter, Code, Bluetooth, Video game

AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Silicon Labs (NASDAQ: SLAB), a leader in secure, intelligent wireless technology for a more connected world, today announced their new xG26 family of Wireless SoCs and MCUs, the IoT industry leader's highest performance device family to date. The new family consists of the multiprotocol MG26 SoC, the Bluetooth LE BG26 SoC, and the PG26 MCU. All three are designed to future-proof the IoT against some of the most demanding emerging applications, like Matter, with double the Flash and RAM of other Silicon Labs multiprotocol devices.

Key Points: 
  • All three are designed to future-proof the IoT against some of the most demanding emerging applications, like Matter , with double the Flash and RAM of other Silicon Labs multiprotocol devices.
  • That's Matter's interoperability and security promise, which is why Silicon Labs designed the MG26 to be the most advanced SoC for the Matter standard.
  • Pin compatibility between select xG26 and xG24 devices and shared hardware and software development tools like Silicon Labs Simplicity Studios allows for easy development and seamless migration from other Silicon Labs Series 2 devices.
  • Learn more about how to begin developing cutting-edge IoT devices using Silicon Labs, be sure to :

CHIPOTLE KICKS OFF PARTNERSHIP WITH TEKKEN™ 8, RETURNS WITH NEW EXCLUSIVE EXPERIENCES FOR THE FIGHTING GAME COMMUNITY (FGC)

Retrieved on: 
Monday, April 8, 2024
Partnership, Reward, FGC, Evo, CMG, Combat, Printing, Chipotle Mexican Grill, PlayStation 5, Internet, Evolution, Challenger Series, CCS, Sony Interactive Entertainment, Code, Ecosystem, Evolution Championship Series, Battlebowl, Grand, Parent, Challenger, Advertising, Food delivery

As a nod to the TEKKEN community, the code EWGF623 pays homage to the iconic "Electric Wind God Fist" move.

Key Points: 
  • As a nod to the TEKKEN community, the code EWGF623 pays homage to the iconic "Electric Wind God Fist" move.
  • Chipotle Rewards members can also redeem 250 points in the Chipotle Rewards Exchange to receive an additional code for 500 TEKKEN COINS**.
  • Chipotle's 2024 edition of its signature esports competition will be hosted in partnership with Sony Interactive Entertainment and feature TEKKEN 8 as its title game.
  • All eligible competitors in the Chipotle Challenger Series will earn free chips & guac from Chipotle.

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

Retrieved on: 
Wednesday, March 20, 2024
Congress, Juntendo University, Dyslipidemia, Patient, SAFETY, Research, Code, MD, Abstract, Type 2 diabetes, HTG, Tokyo Stock Exchange, EAS, Lipid metabolism, NAFLD, T2DM, Pharmaceutical industry

Presentation details will be disseminated as they become available.

Key Points: 
  • Presentation details will be disseminated as they become available.
  • Ph.D., M.P.H., Chief Medical Officer, MediciNova, Inc., commented, “We are very pleased that the two presentations were accepted at the EAS 2024 Congress.
  • One presentation is regarding the objectives and design of the ongoing Phase 2 clinical trial enrolling patients with Type 2 diabetes, dyslipidemia, and NAFLD.
  • The other presentation is regarding the mechanism of action of MN-001/MN-002 in lipid metabolism, particularly the effects on cholesterol efflux capacity.

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Retrieved on: 
Tuesday, March 12, 2024
Abstract, Chlorine, Survival, SOT, University, Doctor of Philosophy, MD, Code, FAHA, Society, Translation, Safety, Tokyo Stock Exchange, ALI, Edema

In this study, single-dose and multi-dose treatments were evaluated.

Key Points: 
  • In this study, single-dose and multi-dose treatments were evaluated.
  • The primary endpoint was the mean change in the pulmonary function measure PaO2/FiO2, which is the ratio of arterial oxygen partial pressure to fractional inspired oxygen.
  • Additional endpoints included survival, lung mechanics, lung injury, and edema formation evaluated by chest x-ray.
  • Cl2 gas concentration of 210 ppm x 30 min was expected to result in a 20 - 30% mortality rate (Fukuda 2015).

CFP Board Imposes Public Sanctions on Nine Additional Individuals

Retrieved on: 
Friday, April 5, 2024
Other Professional Services, Personal Finance, Finance, Asset Management, Consulting, Accounting, Professional Services, Business, Failure, General ledger, NAC, Counsel, Professional services, FINRA, Consent decree, Consent, Employment, Form, Seriousness, Enforcement, Censure, Calendar, Social Security, Documentation, Letter, District court, Code, Commission, Administration, Ethics commission, Associate, DEC, Motion, Complaint, Social, CFP, AWC, Financial Industry Regulatory Authority, Financial adviser

Robert P. Baffa Jr., CFP® (Las Vegas, Nevada): In January 2024, the Disciplinary and Ethics Commission (Commission) issued an order in which Mr. Baffa received a Public Censure.

Key Points: 
  • Robert P. Baffa Jr., CFP® (Las Vegas, Nevada): In January 2024, the Disciplinary and Ethics Commission (Commission) issued an order in which Mr. Baffa received a Public Censure.
  • Pursuant to his Consent Order with CFP Board, the Commission issued Mr. Ercole an Order of Public Censure.
  • Pursuant to this Consent Order with CFP Board, the Commission issued Ms. Hayut a Suspension of One Year and One Day.
  • This sanction followed the expiration of Mr. Kirkpatrick’s CFP® certification and his failure to file an Answer to CFP Board Enforcement Counsel’s Complaint within the required time frame.